CN1682910A - Chinese patent medicine on health food composition and its use - Google Patents
Chinese patent medicine on health food composition and its use Download PDFInfo
- Publication number
- CN1682910A CN1682910A CNA2005100491038A CN200510049103A CN1682910A CN 1682910 A CN1682910 A CN 1682910A CN A2005100491038 A CNA2005100491038 A CN A2005100491038A CN 200510049103 A CN200510049103 A CN 200510049103A CN 1682910 A CN1682910 A CN 1682910A
- Authority
- CN
- China
- Prior art keywords
- test
- health
- food composition
- chinese patent
- patent medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 235000013402 health food Nutrition 0.000 title claims abstract description 9
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 19
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 18
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 18
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 18
- 206010020772 Hypertension Diseases 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 16
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 16
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 16
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 16
- 229940057059 monascus purpureus Drugs 0.000 claims abstract description 16
- 201000005577 familial hyperlipidemia Diseases 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims description 24
- 235000002322 Monascus purpureus Nutrition 0.000 claims description 15
- 244000113306 Monascus purpureus Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 8
- 235000012000 cholesterol Nutrition 0.000 abstract description 4
- 239000000463 material Substances 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 22
- 241000700159 Rattus Species 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical group [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical group C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 8
- 241000053227 Themus Species 0.000 description 7
- 239000013642 negative control Chemical group 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XJGFWWJLMVZSIG-UHFFFAOYSA-N 9-aminoacridine Chemical compound C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 XJGFWWJLMVZSIG-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000032170 Congenital Abnormalities Diseases 0.000 description 4
- 206010061619 Deformity Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CZIHNRWJTSTCEX-UHFFFAOYSA-N 2 Acetylaminofluorene Chemical group C1=CC=C2C3=CC=C(NC(=O)C)C=C3CC2=C1 CZIHNRWJTSTCEX-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960001441 aminoacridine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000003177 cardiotonic effect Effects 0.000 description 2
- QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical group O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010050106 Paroxysmal arrhythmia Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010050208 Teratospermia Diseases 0.000 description 1
- 208000002312 Teratozoospermia Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Natural products C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- -1 anthracene ester Chemical class 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960001577 dantron Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to Chinese medicine or health food composition, and Chinese medicine or health food composition for preventing and treating hyperlipemia, hypertension and fatty liver and its application. The composition has material comprising red yeast 5-60 wt%, soybean isoflavone 0.3-50 wt% and oriental water plantain 10-75 wt% as well as haw and/or cassia seed. The composition of the present invention has no toxic side effect, and excellent fat regulating effect to reduce the content of cholesterol, triglyceride and low density lipoprotein in blood obviously. The composition is used in medicine and health food for preventing and treating hyperlipemia, hypertension and fatty liver.
Description
Technical field
The present invention relates to a kind of Chinese patent medicine or health-care food composition and application thereof that prevents and treats hyperlipemia, hypertension, fatty liver.
Background technology
According to the data show that World Health Organization (WHO) announces, cardiovascular and cerebrovascular disease has become first killer of harm humans health.Raising with low density lipoprotein, LDL and very low density lipoprotein (VLDL) is that the hyperlipemia of feature is to cause atherosclerosis, and then brings out one of main hazard factor of coronary heart disease, simultaneously, might concurrent myocardial ischemia, a series of cardiovascular disease such as angina pectoris.At present, the medicine that is used to prevent and treat hyperlipemia in the world is various in style, and wherein HMG-CoA reductase inhibitor (Statins) is the most effective lipid regulating agent, and treatment severe hyperlipemia has tangible curative effect.But the side effect of chemicals makes medium or slight hyperlipidemia patient be difficult to take for a long time.
Show that according to another the China's Statistical data among 35 to 74 years old crowd of China, hypertensive sickness rate is up to about 27 percent, patient's number is near 100,013,000, and is annual newly-increased more than 3,000,000.Surplus the existing patients with cerebral apoplexy 500 ten thousand, annual neopathy 1,500,000 people, dead 200,000 people.Hypertension can cause the damage of organs such as the heart, brain, kidney, serious threat human beings'health and life.
Fatty liver is that its sickness rate was up to 10～20% due to fat was accumulated in liver in a large number.The transaminase person of increasing about 35% is a fatty liver in adult's health check-up, and part patient can develop into liver cirrhosis.Fatty liver often is associated with blood fat and increases, and the foreign study personnel find that also the Arterial Hypertention patient is than irrelevant fatty livers of other main hazard factor such as the easier appearance of normal person and rising of liver enzyme or hepatitis steatosis.On the other hand, fatty liver takes place and often prompts for pernicious obesity in overweight and overweight people, and the latter and impaired glucose tolerance, hyperlipemia and hypertension are referred to as " dead quartet ", the very easily concurrent mortality cardiovascular and cerebrovascular disease of this class patient.Therefore, Prevention and Management of Fatty Liver is of crucial importance to the progress that stops chronic hepatopathy and the generation that reduces cardiovascular and cerebrovascular disease.
Summary of the invention
The objective of the invention is to overcome problems of the prior art, with medicine food dual-purpose plant is raw material, provides a kind of to preventing and treating Chinese patent medicine or health-care food composition and the application in such medicine of preparation or health food thereof that hyperlipemia, hypertension, fatty liver have positive effect.
Monas cuspurpureus Went is exactly the good merchantable brand of medicine food dual-purpose since ancient times, and having helps digestion invigorates blood circulation, the effect of the dry stomach of spleen invigorating.Monas cuspurpureus Went contains the HMG-CoA reductase inhibitor, has the mechanism of action of statins.Because be natural product, so aspect safety, be much better than synthetic statins.Chinese scholars found also that Monas cuspurpureus Went had the effect of blood fat reducing, blood pressure lowering, blood sugar lowering simultaneously in recent years.
Soybean isoflavone is a natural plants estrogen, it safely, have no side effect.Studies show that soybean isoflavone can reduce the susceptibility of body to the serum LDL oxidation, also can improve the non-oxidizability of serum LDL, the formation of prevention of arterial blood vessel wall atheromatous plaque, anti-hemostatic tube medicated porridge sample sclerosis increases arterial vascular compliance, blood vessel dilating simultaneously.The Japan scientific research personnel finds that also soybean isoflavone also has the effect of blood pressure lowering, anti-apoplexy.
Rhizoma Alismatis is a conventional Chinese medicine.Clinical observation shows that Rhizoma Alismatis extract in the TC, can also reduce the content of triglyceride in the blood (TC) in reducing blood.Single Rhizoma Alismatis preparation all has certain curative effect to IIa, IIb, IV, V-type hyperlipoproteinemia, and is especially best to the curative effect of high TC mass formed by blood stasis.Rhizoma Alismatis can reduce LDL content in the blood, improves the ratio of HDL level and HDL-Ch and TC.To the experimental atherosclerosis rabbit, Rhizoma Alismatis extract can obviously suppress the generation of aortic tunica intima speckle.Rhizoma Alismatis also has slight hypotensive activity, and Rhizoma Alismatis extractum and alisol are exempted from the aortic article contraction to exsomatizing have relexation, can suppress the inflow of calcium ion voltage dependent channel.Rhizoma Alismatis can also be improved the liver fat metabolism, has lipotropy.For the Animal fat liver pathological changes due to hypercholesterolemia, high fat, the low albumen feedstuff, Rhizoma Alismatis water extract or benzene are carried thing can make all that fat content reduces in the liver, and the hepatic injury that CCL4 is caused has protective effect.
Fructus Crataegi has the effect of blood circulation promoting and blood stasis dispelling, is traditional facilitating digestion, the medicine of the greasy meat stagnation that disappears.The blood fat reducing of modern pharmacological research proof Fructus Crataegi energy, blood pressure lowering, atherosclerosis; Increase the coronary vasodilator blood flow, improve the coronary disease circulation, and it is compensatory that the coronary artery sexual exhaustion is able to, reach cardiotonic, and improve the sensitivity of cardiac muscle, increase heart output the cardiotonic glycoside effect, weaken myocardium irritability and conductivity, has anti-ventricular fibrillation, effects such as atrial fibrillation and paroxysmal arrhythmia, and the heartthrob effect that all sets up.
Semen Cassiae is the seed that leguminous plant is stewed leaf Semen Cassiae or Semen Cassiae, includes anthracene ester and anthraquinone glycoside, obtusin and vitamin A etc., and pharmacological testing proves: Semen Cassiae has bringing high blood pressure down and reduces the effect of serum cholesterol; Anti-various pathogens and the effect of soft stool cathartic are arranged.The traditional Chinese medical science is thought, its cold nature, and sweet in the mouth, hardship, the function liver heat removing and eyesight improving, the diuretic relieving constipation is applicable to the puckery pain of conjunctival congestion due to liver-heat or the wind-heat of liver channel, the many tears of photophobia etc.; In addition to the treatment hypertension, hepatitis, cirrhotic ascites and habitual constipation etc. are also effective.
Described a kind of Chinese patent medicine or health-care food composition is characterized in that containing following raw materials by weight proportions and make: Monas cuspurpureus Went 5-60%, soybean isoflavone 0.3%-50%, Rhizoma Alismatis 10-75%.
Described Chinese patent medicine or health-care food composition is characterized in that containing: Monas cuspurpureus Went 5-35%, soybean isoflavone 1%-30%, Rhizoma Alismatis 20-70%.
Described Chinese patent medicine or health-care food composition is characterized in that containing: Monas cuspurpureus Went 10-25%, soybean isoflavone 2%-10%, Rhizoma Alismatis 30-60%.
Described Chinese patent medicine or health-care food composition is characterized in that containing in the crude drug Fructus Crataegi 10-60%, preferred 20-40%, more preferably 20-30%, most preferably 25%.
Described Chinese patent medicine or health-care food composition is characterized in that containing in the crude drug Semen Cassiae 5-60%, preferred 10-40%, more preferably 10-20%, most preferably 15%.
Described Chinese patent medicine or health-care food composition is characterized in that containing: Monas cuspurpureus Went 12%, soybean isoflavone 4%, Rhizoma Alismatis 38%, Fructus Crataegi 28%, Semen Cassiae 18%.
Described Chinese patent medicine or health-care food composition is characterized in that dosage form is a solid preparation, is specially tablet or capsule or granule or electuary.
The purposes of described Chinese patent medicine or health-care food composition is characterized in that preventing and treating the medicine of hyperlipemia, hypertension, fatty liver or the application in the health food in preparation.
The proportioning that relates in the present patent application file is weight percentage or weight proportion.
According to said ratio, utilize conventional production process to carry out the extraction of effective ingredient, add conventional adjuvant and fully make finished product after the mixing by different dosage form, can be tablet or capsule or granule or electuary.Because of the adjuvant that adds and consumption, concrete production technology all belong to existing known technology, do not repeat them here.
The recommended amounts of the present composition: tablet, capsule preparations are 2.0g/ people/sky, and granule, electuary are 4.0g/ people/sky, and be oral at twice, swallow or take after mixing it with water according to the different waters of dosage form.
The present composition has no side effect, regulating lipid is good, can significantly reduce cholesterol in the blood, triglyceride, low density lipoprotein, LDL, positive effect also be arranged, can apply to prepare medicine or the health food of preventing and treating hyperlipemia, hypertension, fatty liver preventing and treating hypertension, fatty liver.
The specific embodiment
By the following examples the present invention is elaborated, and further specify beneficial effect of the present invention with animal and clinical trial example.Following prescription is the weight in grams number of crude drug.
The tablet of embodiment 1:0.5g/ sheet
Composition (1) 1000 (2) 1000 consumption of consumption of 1000 consumptions (3)
Monas cuspurpureus Went 250g 250g 250g
Soybean isoflavone 40g 40g 40g
Rhizoma Alismatis 1000g 1000g 1000g
Fructus Crataegi 1000g 1000g-
Semen Cassiae 500g--
The capsule of embodiment 2:0.5g/ grain
Composition (1) 1000 (2) 1000 consumption of consumption of 1000 consumptions (3)
Monas cuspurpureus Went 250g 250g 250g
Soybean isoflavone 40g 40g 40g
Rhizoma Alismatis 1000g 1000g 1000g
Fructus Crataegi 1000g 1000g-
Semen Cassiae 500g--
The granule of embodiment 3 2g/ bag
Composition 1000 bag consumptions (1) 1000 bag consumption (2) 1000 bag consumptions (3)
Monas cuspurpureus Went 500g 500g 500g
Soybean isoflavone 80g 80g 80g
Rhizoma Alismatis 2000g 2000g 2000g
Fructus Crataegi 2000g 2000g-
Semen Cassiae 1000g--
The electuary of embodiment 4 electuary 2g/ bag
Composition 1000 bag consumptions (1) 1000 bag consumption (2) 1000 bag consumptions (3)
Monas cuspurpureus Went 500g 500g 50g
Soybean isoflavone 80g 80g 80g
Rhizoma Alismatis 2000g 2000g 2000g
Fructus Crataegi 2000g 2000g-
Semen Cassiae 1000g--
One, safety toxicology test
1 materials and methods
1.1 tried thing: plant the capsule that prescription production obtains by the embodiment of the invention 2 (1), below all be called for short and tried thing, prosperous rich Pharma Inc. provides by Hangzhou.
1.2 experimental animal: ICR mice, cleaning level; The SD rat, the cleaning level.The medical experiment animal quality certification numbers 2001001 is provided by Zhejiang Province's Experimental Animal Center.
2 acute toxicity tests
SD rat body weight 180-220g, each 20 of male and female; ICR mice body weight 18-22g, each 20 of male and female.By horn method SD rat, ICR mice are divided into 1.00g/kg, 2.15g/kg, 4.64g/kg, four dosage groups of 10.00g/kg body weight at random, each 5 of every group of male and female.Each treated animal is after stopping eating 16 hours, and disposable per os is tried thing, observes general situation, poisoning symptom and the death condition of rat and mice, is tried the half lethal dose LD of thing to rat and mice to determine this
50, observe 2 weeks of time limit, the results are shown in Table 1.
Table 1 is tried the acute toxicity of thing to rat and mice
| Dosage (g/kg) | Female | Male | Reaction of animals | ????LD 50(g/kg body weight) | |||
| Number of animals | Death toll | Number of animals | Death toll | ||||
| The SD rat | ????1.00 ????2.15 ? ????4.64 ????10.0 | ????5 ????5 ? ????5 ????5 | ????0 ????0 ? ????0 ????0 | ????5 ????5 ? ????5 ????5 | ????0 ????0 ? ????0 ????0 | Normal | ? ? ????＞10 ? ? |
| The ICR mice | ????1.00 ? ????2.15 ? ????4.64 ????10.0 | ????5 ? ????5 ? ????5 ????5 | ????0 ? ????0 ? ????0 ????0 | ????5 ? ????5 ? ????5 ????5 | ????0 ? ????0 ? ????0 ????0 | Normal | ? ? ? ????＞10 ? ? |
3 genetic toxicity tests
3.1 Salmonella reversion test: select the histidine auxotroph Salmonella typhimurium for use, totally four strains, i.e. TA
97A, TA
98, TA
100, TA
102, establish five dosage groups of 5000,1000,200,40,8 μ g/ wares, each dosage is established three parallel wares, and repeated trials is once.Positive controls: 9-aminoacridine, 2,7 diamin of luorene, sodium azide, 2-acetamidofluorene, ametycin, 1,8-dihydroxyanthraquinone; Negative control group: distilled water.Observe that returning of each bacterial strain becomes clump count on the counting culture medium, result of the test sees Table 2, table 3.
Table 2 is tried the dull and stereotyped infiltration test result of thing Ames
| Dosage (μ g/ ware) | Return to become clump count (X ± SD) | ||||||||
| ?TA97a | ?TA98 | ?TA100 | ?TA102 | ||||||
| ?-S9 | ?+S9 | ?-S9 | ?+S9 | ?-S9 | ??+S9 | ?-S9 | ??+S9 | ||
| Tried thing | ??0 ??8 ??40 ? ??200 ??1000 ??5000 | ?156.3±11.59 ?146.7±23.18 ?160.0±12.00 ? ?156.7±11.93 ?152.3±4.04 ?162.3±11.93 | ?174.7±5.77 ?172.3±11.93 ?168.3±8.39 ? ?165.0±7.55 ?162.3±8.50 ?172.7±10.07 | ?30.7±2.31 ?30.3±2.08 ?31.3±2.52 ? ?29.7±2.89 ?30.7±3.21 ?30.7±2.52 | ?37.7±3.51 ?39.0±2.65 ?39.7±4.04 ? ?37.3±3.21 ?41.0±2.65 ?40.0±2.65 | ?166.7±14.01 ?157.7±8.39 ?161.3±6.03 ? ?160.3±11.59 ?167.0±12.53 ?157.3±7.23 | ??179.0±12.53 ??184.3±7.23 ??190.3±13.58 ? ??187.3±6.43 ??186.3±11.50 ??186.7±13.61 | ?259.7±11.59 ?262.0±18.33 ?263.7±18.01 ? ?161.7±12.34 ?256.0±11.14 ?255.0±10.44 | ??295.7±6.51 ??287.3±14.74 ??293.7±17.56 ? ??290.3±12.10 ??315.0±6.56 ??296.7±10.07 |
| ??9AA | ??25 | ?＞1000 | |||||||
| ??2.7AF | ??20 | ?330 | |||||||
| ??NaN3 | ??1.5 | ?＞1000 | |||||||
| ??2AAF | ??10 | ?＞1000 | ?＞1000 | ??＞1000 | |||||
| ??MMC | ??0.5 | ?＞1000 | |||||||
| ??1.8HAQ | ??25 | ??＞1000 | |||||||
Table 3 is tried the dull and stereotyped infiltration test of thing Ames repeated trials result as a result
| Tried thing | Dosage (μ g/ ware) | Return to become clump count (X ± SD) | |||||||
| ?TA97a ? | ?TA98 ? | ?TA100 ? | ??TA102 ? | ||||||
| ?-S9 | ?+S9 | ?-S9 | ?+S9 | ?-S9 | ??+S9 | ??-S9 | ?+S9 | ||
| Tried thing | ?0 ?8 ?40 ? ?200 ?1000 ?5000 | ?152.0±6.00 ?154.0±7.94 ?155.7±11.85 ? ?151.0±16.64 ?160.3±8.62 ?162.7±10.07 | ?177.0±10.44 ?166.7±10.26 ?162.3±11.93 ? ?174.7±9.45 ?166.0±8.89 ?176.0±8.72 | ?31.0±2.65 ?30.0±2.00 ?31.0±1.73 ? ?31.7±2.08 ?34.0±2.65 ?30.0±1.00 | ?39.0±2.65 ?39.3±4.16 ?41.3±1.53 ? ?38.7±3.06 ?37.7±3.06 ?38.0±2.00 | ?170.7±14.74 ?161.3±12.22 ?158.3±13.87 ? ?153.7±10.21 ?157.3±6.03 ?165.7±20.98 | ??175.3±12.34 ??164.3±14.57 ??157.0±5.57 ? ??160.3±12.01 ??170.0±9.85 ??175.3±15.14 | ??248.7±13.01 ??259.0±10.44 ??272.7±8.33 ? ??257.7±14.50 ??258.7±13.32 ??260.3±15.50 | ?296.0±7.00 ?293.0±7.81 ?306.0±5.29 ? ?295.7±6.51 ?295.0±15.39 ?297.7±9.45 |
| ?9AA | ?25 | ?＞1000 | |||||||
| ?2.7AF | ?20 | ?321 | |||||||
| ?NaN3 | ?1.5 | ?＞1000 | |||||||
| ?2AAF | ?10 | ?＞1000 | ?＞1000 | ??＞1000 | |||||
| ?MMC | ?0.5 | ??＞1000 | |||||||
| ?1.8HAQ | ?25 | ?＞1000 | |||||||
9AA 9-aminoacridine 2.7AF 2.7-N-2-Fluorenylamine NaN3 sodium azide
2AAF 2-acetamidofluorene MMC ametycin 1.8HAQ 1.8-hydroxyanthraquinone
3.2 mouse marrow cell micro nuclear test: ICR mice body weight 25-28g.Mice divides 2.5,5.0 at random, three dosage groups of 10.0g/kg body weight, a negative control group (1% carboxymethyl cellulose) and a positive controls (cyclophosphamide 40mg/kg body weight), 10 every group, each 5 of male and female.Tried thing and be mixed with corresponding dosage with 1% carboxymethyl cellulose.Mice is 24 hours continuous irrigation stomaches 2 times at interval, in irritating for the second time the stomach execution that dislocates after 6 hours.Get bone marrow of sternum and make the bone marrow sheet, methanol is fixed, Giemsa dyeing.1000 polychromatic erythrocytes of every animal counting calculate micronucleus and do the branch rate when observing microscopy, the results are shown in Table 4.
Table 4 is tried the influence of thing to the micronuclei in mice rate
| Sex | Group | Dosage (g/kg) | The Mus number | The polychromatic erythrocyte number | The micronucleus cell number | Micronuclear rates (‰) |
| Female | Negative control | ??0.0 | ????5 | ????5000 | ????9 | ??1.8 |
| Tried thing | ? ??2.5 | ? ????5 | ? ????5000 | ? ????7 | ? ??1.4 | |
| ??5.0 | ????5 | ????5000 | ????9 | ??1.8 | ||
| ??10.0 | ????5 | ????5000 | ????8 | ??1.6 | ||
| Cyclophosphamide | ??0.04 | ????5 | ????5000 | ????74 | ??14.8* | |
| Male | Negative control | ??0.0 | ????5 | ????5000 | ????7 | ??1.4 |
| Tried thing | ??2.5 | ????5 | ????5000 | ????10 | ??2.0 | |
| ??5.0 | ????5 | ????5000 | ????8 | ??1.6 | ||
| ??10.0 | ????5 | ????5000 | ????9 | ??1.8 | ||
| Cyclophosphamide | ??0.04 | ????5 | ????5000 | ????76 | ??15.2* |
Annotate * P＜0.01 (with the negative control group ratio)
3.3 mouse sperm deformity test: 50 of ICR male mices, body weight 21-25g.2.5,5.0, three dosage groups of 10.0g/kg body weight if, a negative control group (1% carboxymethyl cellulose) and a positive controls (ametycin 2.0mg/kg body weight), 10 every group.Sample gives to irritate the stomach mode, and continuous 5 days, once a day, matched group is same treatment also.Dislocation is put to death after the 35th day after irritating stomach first, and every group is selected 5 mices to get the both sides epididymis respectively at random, makes suction strainer liquid direct smear, natural drying, and methanol is fixed, and dyes with 1% Yihong.Observe sperm morphology and counting under high power lens, every mice is counted 1000 of complete sperms, calculates sperm deformity incidence rate (%), the results are shown in Table 5.
Table 5 is tried the influence of thing to the mouse sperm deformity incidence rate
| Group | Dosage (g/kg) | The Mus number | Observe sperm count | The teratospermia number | Subtotal | Micronuclear rates (‰) | ||||||
| Indefiniteness | Wugou | Folding | Fat head | Fructus Musae | Double end | Two tails | ||||||
| Tried thing | ????0.0 | ????5 | ??5000 | ??67 | ??4 | ????1 | ??72 | ????1.44 | ||||
| ????2.5 ? | ????5 ? | ??5000 ? | ??71 ? | ??6 ? | ????1 ? | ??78 ? | ????1.56 ? | |||||
| ????5.0 | ????5 | ??5000 | ??75 | ??3 | ????2 | ??80 | ????1.60 | |||||
| ????10.0 | ????5 | ??5000 | ??68 | ??3 | ????1 | ??72 | ????1.44 | |||||
| ??MMC | ????0.002 | ????5 | ??5000 | ??246 | ??24 | ????20 | ????20 | ????18 | ??328 | ????6.56* | ||
Annotate: MMC ametycin * P＜0.01 (with the negative control group ratio)
30 days feeding trials of 4 rats
The SD rat is divided into 4 groups at random, 20 every group, male and female half and half.Matched group is established in test, is tried thing 1.25,2.5,3.3g/kg body weight group.Being tried thing gives to mix feedstuff mode mode.Ad lib, drinking-water write down body weight and food-intake weekly and calculate food utilization.Experiment end of term overnight fasting, next day sacrificed by decapitation, taking internal organ is weighed and is compared group and the liver of high dose group, nephropathy are managed cut sections for microscopic examination, gets blood and carries out hemogram, blood biochemical analysis.Experimental result sees Table 6, table 7, table 8, table 9, table 10.
Table 6 is tried the influence of thing to rat body weight
| Sex | Dosage (g/kg) | The Mus number | Starting weight (g) | First week (g) | Second week (g) | The 3rd week (g) | Around (g) |
| Female | ?0.0 ?1.25 ? ?2.5 ?3.3 | ?10 ?10 ? ?10 ?10 | ?77.6±4.8 ?77.7±4.4 ? ?77.7±5.3 ?76.7±5.7 | ?123.4±8.7 ?120.9±6.6 ? ?123.7±7.6 ?121.1±6.4 | ?159.9±10.0 ?159.3±9.4 ? ?154.3±7.2 ?155.4±7.3 | ?178.1±10.5 ?181.7±9.8 ? ?180.1±9.4 ?179.9±9.2 | ?205.6±10.4 ?211.9±11.6 ? ?207.6±12.5 ?206.1±9.8 |
| Male | ?1.0 ?1.25 ? ?2.5 ?3.3 | ?10 ?10 ? ?10 ?10 | ?80.6±6.1 ?80.8±5.4 ? ?80.6±4.0 ?80.8±5.0 | ?140.9±10.6 ?138.6±8.8 ? ?137.0±5.0 ?135.9±7.4 | ?196.5±14.1 ?190.1±10.3 ? ?190.5±13.6 ?184.6±15.9 | ?240.3±16.8 ?235.5±17.2 ? ?241.6±15.0 ?232.6±24.9 | ?275.9±22.6 ?260.3±17.6 ? ?274.8±15.5 ?268.3±24.1 |
Table 7 is tried the influence of thing to weightening finish, food-intake and the food utilization of rat
| Sex | Dosage (g/kg) | The Mus number | Weightening finish (g) | Food-intake (g) | Food utilization (g) |
| Female | ????0.0 ????1.25 ? ????2.5 ????3.3 | ????10 ????10 ? ????10 ????10 | ????128.0±9.3 ????134.2±12.1 ? ????129.9±10.3 ????129.4±13.1 | ?534.0±23.2 ?535.5±18.6 ? ?536.7±24.4 ?539.6±17.5 | ??23.97±1.37 ??25.04±1.78 ? ??24.19±1.32 ??23.98±2.27 |
| Male | ????1.0 ????1.25 ? ????2.5 ????3.3 | ????10 ????10 ? ????10 ????10 | ????195.3±21.2 ????179.5±18.7 ? ????194.2±15.4 ????187.5±25.0 | ?686.3±32.5 ?666.7±23.6 ? ?685.3±21.8 ?669?3±26.5 | ??28.40±2.10 ??26.88±2.13 ? ??28.30±1.36 ??27.93±2.82 |
Table 8 is tried the influence of thing to the rat hemogram
| Sex | Dosage (g/kg) | The Mus number | Erythrocyte (* 1012/L) | Hemoglobin (g/L) | Leukocyte (* 109/L) | Leukocyte differential count (%) | ||
| Lymph | Neutral | Other | ||||||
| Female | ????0.0 ????1.25 ????2.5 ????3.3 | ????10 ????10 ????10 ????10 | ????8.55±0.33 ????7.93±0.33 ????8.15±0.64 ????7.89±0.38 | ????156.17.4 ????155.4±4.4 ????156.9±4.9 ????157.9±6.7 | ????14.15±2.93 ????11.01±2.04 ????11.30±3.71 ????13.86±3.50 | ????79.2 ????79?2 ????80.0 ????84.0 | ????19.4 ????20.1 ????19.0 ????14.0 | ????1.4 ????0.7 ????1.0 ????2.0 |
| Male | ????0.0 ????1.25 ????2.5 ????3.3 | ????10 ????10 ????10 ????10 | ????8.13±0.34 ????8.99±1.11 ????8.80±1.68 ????8.32±1.46 | ????155.9±7.7 ????172.9±16.8 ????172.8±24.7 ????163.8±19.0 | ????13.48±3.51 ????12.30±2.94 ????13.85±3.35 ????13.46±1.82 | ????79.5 ????74.3 ????78.5 ????81.1 | ????19.4 ????24.3 ????19.4 ????15.5 | ????1.1 ????1.4 ????2.1 ????3.4 |
Table 9 is tried the influence of thing to blood biochemistry of rats
| Sex | Dosage (g/kg) | The Mus number | ??ALT ?(IU/L) | ??TP ??(g/L) | ??ALB ??(g/L) | ??TG ??(mmol/L) | ??Chol ??(mmol/L) | ??Glu ??(mmol/L) | ??Urea ??(mmol/L) | ??CR ??(umol/L) |
| Female | ??0.0 ??1.25 ??2.5 ??3.3 | ??10 ??10 ??10 ??10 | ?60.3±7.0 ?69±11.1 ?61.9±9.3 ?56.1±7.4 | ??68.0±3.5 ??69.4±4.7 ??70.9±6.1 ??65.4±3.7 | ??36.3±1.8 ??38.5±2.2 ??39.2±3.6 ??35.8±1.6 | ??0.46±0.36 ??0.37±0.20 ??0.28±0.11 ??0.31±0.21 | ??1.84±0.27 ??1.90±0.19 ??1.70±0.31 ??1.76±0.29 | ??4.22±0.57 ??3.90±0.57 ??4.06±0.65 ??3.73±0.45 | ??5.63±0.96 ??6.41±1.09 ??6.04±0.73 ??6.09±1.22 | ??48.6±3.0 ??52.6±3.3 ??50.7±6.3 ??45.8±7.0 |
| Male | ??0.0 ??1.25 ??2.5 ??3.3 | ??10 ??10 ??10 ??10 | ??88.3±10.3 ??81.0±14.6 ??81.3±9.9 ??89.2±11.2 | ??62.7±3.1 ??63.7±1.5 ??62.8±2.5 ??67.0±3.0 | ??34.9±1.2 ??34.4±1.1 ??34.0±1.4 ??36.1±1.6 | ??0.50±0.11 ??0.41±0.14 ??0.37±0.16 ??0.52±0.21 | ??1.78±0.38 ??1.57±0.38 ??1.57±0.15 ??1.71±0.36 | ??4.13±0.25 ??3.28±0.78 ??3.62±0.69 ??3.79±0.67 | ??6.23±1.04 ??6.47±1.30 ??6.48±0.77 ??6.42±0.87 | ??46.3±5.1 ??50.4±7.6 ??48.1±3.5 ??48.7±4.2 |
Table 10 is tried the influence of thing to the dirty body ratio of rat
| Sex | Dosage (g/kg) | The Mus number | The liver body is than (%) | The kidney body is than (%) | The spleen body is than (%) | The testis body is than (%) |
| Female | ????0.0 ????1.25 ????2.5 ????3.3 | ????10 ????10 ????10 ????10 | ??3.43±0.15 ??3.22±0.16 ??3.23±0.17 ??3.31±0.36 | ????0.90±0.08 ????0.92±0.06 ????0.93±0.05 ????0.95±0.08 | ??0.26±0.02 ??0.25±0.05 ??0.24±0.02 ??0.26±0.07 | |
| Male | ????0.0 ????1.25 ????2.5 ????3.3 | ????10 ????10 ????10 ????10 | ??3.37±0.22 ??3.41±0.15 ??3.30±0.18 ??3.37±0.18 | ????0.97±0.04 ????0.97±0.07 ????1.00±0.05 ????0.98±0.04 | ??0.23±0.04 ??0.25±0.02 ??0.22±0.03 ??0.23±0.03 | ??0.94±0.07 ??0.94±0.12 ??0.98±0.07 ??0.96±0.08 |
5 conclusions
According to this result of the test, compositions of the present invention is to the large and small Mus per os of male and female LD
50All greater than the 10.00g/kg body weight, true border is nontoxic.Salmonella reversion test, mouse marrow cell micro nuclear test, mouse sperm deformity result of the test are all negative.30 days feeding trial results of rat do not see that poisoning symptom appears in laboratory animal, and unusual pathological change is seen in gross anatomy also end, the influence of all harmless property of routine blood test and biochemical indicator.
Two, clinical trial
In order to verify the drug effect of the present composition, entrust Zhejiang Center For Disease Control and Prevention and Zhejiang Province to stand and finish human feeding trial jointly with moral hospital.
1 materials and methods
1.1 sample: plant the tablet that prescription production obtains by the embodiment of the invention 1 (1), below all be called for short and tried thing; Placebo (starch), prosperous rich Pharma Inc. provides by Hangzhou, and the two is in full accord on packing, outward appearance, color and luster and mouthfeel, and recommended intake is 2.0g/ day.
1.2 the experimenter selects: the age requires to keep usual diet at the hyperlipemia in 18-65 year, and blood sampling is 2 times in half a year, and its serum total cholesterol (TC) 〉=5.2mmol/L or serum levels of triglyceride (TG) 〉=1.65mmol/L person all can include test in.
1.3 test method: adopt the double blind random grouping, between group and self two kinds of control design.According to above-mentioned Standard Selection 100 routine hyperlipemias, patient's 25 examples of complicated hypertension wherein merge patient's 18 examples of fatty liver.By age, sex, blood lipid level etc. are divided into two groups of test-meal group and matched groups, wherein test-meal group 50 examples, matched group 50 examples at random.The test-meal group is taken and is tried thing, and every day 2 times, each 2, matched group is taken placebo, and instructions of taking was taken 30 days continuously with the test-meal group.
1.4 observation index: each tests once every index when test-meal begins and finish.
Safety indexes: blood, urine, stool routine examination inspection comprise blood rbc counting (RBC), hemoglobin (Hb), numeration of leukocyte (WBC); Biochemical indicator comprises glutamic oxaloacetic transaminase, GOT (AST), glutamate pyruvate transaminase (ALT), total serum protein (TP), albumin (ALB), blood glucose (GLU), blood urea nitrogen (BUN), creatinine (Cr); Electrocardiogram; Abdominal B type ultrasonography; The fluoroscopy of chest of X line.
Effect index: get blood on an empty stomach, measure serum total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) level and reduce percentage rate, HDL-C (HDL-C) level and ascensional range.
1.5 criterion of therapeutical effect
Effectively: TC reduces＞10%; TG reduces＞15%; HDL-C rising＞0.104mmol/L.
Invalid: as not reach effective standard.
2 result of the tests
2.1 clinical observation: take and tried thing one month, test-meal group clinical observation total effective rate is 74%, with matched group (28%) significance meaning (X is arranged relatively
2=21.168, P=0.000).Clinical observation result sees Table 11.
Table 11 clinical observation effect relatively
The check of group example number (n) enabledisable total effective rate % significance meaning
Matched group 50 14 36 28.00 X
2=21.168
Test-meal group 50 37 13 74.00 P=0.000
2.2 T-CHOL: the T-CHOL variation sees Table 12 before and after the test-meal.Table 12 shows, because initial data heterogeneity of variance (P＜0.05), so adopt t ' check between organizing during relatively significance test.Compare before cholesterol and the test-meal after the test-meal of test-meal group, difference has significance meaning (t=3.820, P＜0.01), with the matched group comparing difference significance meaning (t=2.433, P＜0.05) is arranged also; Its average decline percentage rate is 10.17%, with matched group (0.42%) relatively, difference also have the significance meaning (t '=3.114, P＜0.01).
Cholesterol variation before and after the table 12 liang group test-meal (mmol/L, x ± SD)
Fall decline percentage rate t P after the test-meal before the test-meal of group example number (n)
Matched group 50 5.63 ± 1.17 5.56 ± 1.18 0.07 ± 0.71 0.42 ± 11.74 0.683 0.498
Test-meal group 50 5.89 ± 1.35 5.08 ± 0.71
* #0.81 ± 1.50
##10.17 ± 3.820 0.000
18.78
##
t’??????????????1.055
a?????2.433
a???????3.158??????????3.114
P????????0.294???????0.017?????????0.002??????????0.003
Annotate: *: with comparison P＜0.01 before the test-meal; #: compare P＜0.05 with matched group; ##: compare P＜0.01 with matched group; A: variance is neat.
2.3 triglyceride: the triglyceride variation sees Table 13 before and after the test-meal.Table 13 shows, because initial data heterogeneity of variance (P＜0.05), so adopt t ' check between organizing during relatively significance test.After the test-meal of test-meal group before triglyceride and the test-meal relatively, difference has significance meaning (t=7.546, P＜0.01), with the matched group comparing difference also have the significance meaning (t '=4.950, P＜0.05); Its average decline percentage rate is 25.05%, with matched group relatively, difference also have the significance meaning (t '=6.897, P＜0.01).
Triglyceride variation before and after the table 13 liang group test-meal (mmol/L, x ± SD)
Fall decline percentage rate t P after the test-meal before the test-meal of group example number (n)
Matched group 50 2.63 ± 0.59 2.54 ± 0.09 ± 0.55 1.32 ± 16.36 1.189 0.240
0.42
Test-meal group 50 2.86 ± 0.86 2.07 ± 0.79 ± 0.74
#25.05 ± 18.00
#7.546 0.000
0.52
*#
t’??????????????1.570
a?????4.950
a????5.337????????6.897
P????????0.120???????0.000??????0.000????????0.000
Annotate: *: with comparison P＜0.01 before the test-meal; #: compare P＜0.01 with matched group; A: variance is neat.
2.4 HDL-C: the HDL-C variation sees Table 14 before and after the test-meal.Table 14 shows, because initial data heterogeneity of variance (P＜0.05), so adopt t ' check between organizing during relatively significance test.HDL-C is respectively at comparing difference there are no significant meaning (P＞0.05) between group before and after the test-meal, and test-meal group and matched group are respectively at comparison before and after the test-meal, and difference does not have significance meaning (P＞0.05) yet.
HDL-C variation before and after the table 14 liang group test-meal (mmol/L, x ± SD)
Fall t P after the test-meal before the test-meal of group example number (n)
Matched group 50 1.55 ± 0.25 1.50 ± 0.20 0.053 ± 0.21 1.738 0.088
Test-meal group 50 1.53 ± 0.44 1.52 ± 0.41 0.007 ± 0.27 0.185 0.854
t’??????????????0.292?????????0.388?????????0.944
a
P????????0.771?????????0.699?????????0.348
Annotate: a: variance is neat.
2.5 low-density lipoprotein cholesterol: the variation of low-density lipoprotein cholesterol sees Table 15 before and after the test-meal.Table 15 shows, compares before low-density lipoprotein cholesterol and the test-meal after the test-meal of test-meal group, and difference has highly significant (P＜0.01), with the matched group comparing difference significance (P＜0.05) is arranged also.
The variation of low-density lipoprotein cholesterol before and after the table 15 liang group test-meal (mmol/L, x ± SD)
Fall after the test-meal before the test-meal of group example number (n)
Matched group 50 3.18 ± 0.58 3.11 ± 0.74 0.08 ± 0.40
Test-meal group 50 3.24 ± 0.65 2.83 ± 0.50
* #0.41 ± 0.52
##
Annotate: *: with comparison P＜0.01 before the test-meal; #: compare P＜0.05 with matched group; ##: compare P＜0.01 with matched group.
2.6 security inspection: during being tried, experimenter's stool routine examination and routine urianlysis there is no abnormal change.All in normal range, see Table 16 before and after two groups of hemogram and the test-meal of the every inspection index of hepatic and renal function.
The variation of hemogram and hepatic and renal function before and after table 16 test-meal (x ± SD)
| Project | Matched group (n=50) | Test-meal group (n=50) | ||
| Before the test-meal | After the test-meal | Before the test-meal | After the test-meal | |
| Erythrocyte (* 10 12/ L) leukocyte (* 10 9/ L) hemoglobin (g/L) total serum protein (g/L) albumin (g/L) glutamic-pyruvic transaminase (glutamic-oxalacetic transaminease of μ/L) (blood sugar (mmol/L) urea nitrogen (mmol/L) creatinine (μ mol/L) of μ/L) | ????4.61±0.37 ????5.01±0.65 ????142.14±14.15 ????79.92±3.16 ????47.29±2.57 ????28.14±11.92 ????26.34±6.70 ????4.33±0.36 ????3.71±0.70 ????67.98±13.93 | ????4.57±0.32 ????5.10±0.55 ????141.94±13.27 ????79.59±2.31 ????46.17±1.83 ????25.92±8.16 ????24.06±7.70 ????4.48±0.30 ????3.55±0.53 ????66.72±9.15 | ??4.61±0.46 ??5.68±1.25 ??142.62±16.62 ??79.34±3.05 ??47.16±2.32 ??29.88±13.67 ??26.90±8.46 ??4.28±0.40 ??3.78±0.89 ??67.70±13.06 | ??4.62±0.42 ??5.24±0.83 ??142.84±16.26 ??79.37±2.30 ??46.13±1.12 ??26.84±9.46 ??22.88±7.28 ??4.42±0.26 ??3.74±0.73 ??66.60±7.73 |
3 conclusion (of pressure testing)s
According to this result of the test, the present invention's compositions can reduce serum total cholesterol and triglyceride level, test-meal group self reaches relatively that comparing difference all has significance meaning (P＜0.05) between two groups, wherein T-CHOL on average descends 10.17%, triglyceride on average descends 25.05%, and HDL-C level and matched group relatively do not have obvious decline.Total effective rate is 74%, compares with matched group (28%), and difference has significance meaning (P＜0.01).Also find in the test, 25 routine patients of complicated hypertension, after taking medicine, 21 routine patient's blood pressures obviously reduce; The 18 routine patients that merge fatty liver, by taking the photograph the sheet contrast, medication 11 routine patients' fibrosis after two months obviously alleviates.
In sum, the present composition has no side effect, and has significant accent blood fat, also has positive effect to preventing and treating hypertension, fatty liver, can make medicine or health food that hyperlipemia, hypertension, Patients with Fatty Liver can be taken for a long time.
Claims (9)
1. Chinese patent medicine or health-care food composition is characterized in that containing following raw materials by weight proportions and make: Monas cuspurpureus Went 5-60%, soybean isoflavone 0.3%-50%, Rhizoma Alismatis 10-75%.
2. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that containing: Monas cuspurpureus Went 5-35%, soybean isoflavone 1%-30%, Rhizoma Alismatis 20-70%.
3. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that containing: Monas cuspurpureus Went 10-25%, soybean isoflavone 2%-10%, Rhizoma Alismatis 30-60%.
4. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that containing in the crude drug Fructus Crataegi 10-60%, preferred 20-40%, more preferably 20-30%, most preferably 25%.
5. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that containing in the crude drug Semen Cassiae 5-60%, preferred 10-40%, more preferably 10-20%, most preferably 15%.
6. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that containing: Monas cuspurpureus Went 12%, soybean isoflavone 4%, Rhizoma Alismatis 38%, Fructus Crataegi 28%, Semen Cassiae 18%.
7. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that dosage form is a solid preparation.
8. Chinese patent medicine according to claim 1 or health-care food composition is characterized in that dosage form is tablet or capsule or granule or electuary.
9. according to claim 1 or 7 or 8 described compositionss, it is characterized in that preventing and treating the medicine of hyperlipemia, hypertension, fatty liver or the application in the health food in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100491038A CN1325089C (en) | 2005-02-06 | 2005-02-06 | Chinese patent medicine on health food composition and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100491038A CN1325089C (en) | 2005-02-06 | 2005-02-06 | Chinese patent medicine on health food composition and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1682910A true CN1682910A (en) | 2005-10-19 |
| CN1325089C CN1325089C (en) | 2007-07-11 |
Family
ID=35262529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100491038A Expired - Fee Related CN1325089C (en) | 2005-02-06 | 2005-02-06 | Chinese patent medicine on health food composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1325089C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPI20110038A1 (en) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | FUNCTIONAL FOOD COMPOSITION BASED ON FLOUR. |
| CN102940209A (en) * | 2011-08-15 | 2013-02-27 | 曾广宁 | Health food for preventing and removing extra fat in liver and preparation method thereof |
| CN108186920A (en) * | 2018-02-02 | 2018-06-22 | 金华寿仙谷药业有限公司 | A kind of pharmaceutical composition with auxiliary lipid-lowering efficacy and preparation method thereof |
| CN110170027A (en) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | A kind of haw monascus powder pill and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1216613C (en) * | 2001-07-05 | 2005-08-31 | 深圳太太药业有限公司 | Health-care product capable of regulating blood-lipid and its preparation method |
| CN1248700C (en) * | 2003-04-14 | 2006-04-05 | 李朝晖 | Health-care food for preventing and treating hyperlipoidemia |
| CN1287807C (en) * | 2003-09-06 | 2006-12-06 | 郭凌云 | Blood fat regulating drug or health food |
-
2005
- 2005-02-06 CN CNB2005100491038A patent/CN1325089C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPI20110038A1 (en) * | 2011-04-08 | 2012-10-09 | Funcional Food Res S R L | FUNCTIONAL FOOD COMPOSITION BASED ON FLOUR. |
| WO2012137163A1 (en) * | 2011-04-08 | 2012-10-11 | Funcional Food Research S.R.L. | Flour-based functional food |
| CN102940209A (en) * | 2011-08-15 | 2013-02-27 | 曾广宁 | Health food for preventing and removing extra fat in liver and preparation method thereof |
| CN102940209B (en) * | 2011-08-15 | 2013-12-18 | 曾广宁 | Health food for preventing and removing extra fat in liver and preparation method thereof |
| CN108186920A (en) * | 2018-02-02 | 2018-06-22 | 金华寿仙谷药业有限公司 | A kind of pharmaceutical composition with auxiliary lipid-lowering efficacy and preparation method thereof |
| CN110170027A (en) * | 2019-04-23 | 2019-08-27 | 广东健信制药股份有限公司 | A kind of haw monascus powder pill and preparation method thereof |
| CN110170027B (en) * | 2019-04-23 | 2021-06-29 | 广东健信制药股份有限公司 | Hawthorn and monascus powder pills and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1325089C (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100337662C (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1646150A (en) | Novel use of the extract of processed ginseng and saponin isolated therefrom | |
| CN1706280A (en) | Health food capable of raising immunity and its production process | |
| CN1682910A (en) | Chinese patent medicine on health food composition and its use | |
| CN1305405C (en) | Health food with subsidiary function of lowering blood sugar and lowering blood fat and its production process | |
| CN1255138C (en) | Chinese medicine preparation with accessory protection action to alcoholic liver injury and preparing method thereof | |
| CN102188486B (en) | Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof | |
| CN1529609A (en) | Herbal drug composition for cartilage protection | |
| CN1785054A (en) | Health-care food having anti-oxidation function and its prepn. method | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1297290C (en) | Medicinal composition for treating coronary heart disease and stenocardia and its preparation method | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN101036722A (en) | Health-caring food for easing and improving climacteric Syndrome of men and the preparation thereof | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN1099293C (en) | Hypolipemic medicine and its preparing process and application | |
| CN1686519A (en) | Medicinal composition for preventing alcoholic liver damage | |
| CN1201774C (en) | Medicine for treat hyperlipemia | |
| CN1319588C (en) | Theory and medicine for treating high blood fat, fatty liver, liver fibrosis and preparation method | |
| CN1231255C (en) | Capsule formula for treating astriction prepared using pumpkin as main raw material and its preparation method | |
| CN1539429A (en) | Deoxyadenosine in aplication of preparing bypolipidemic | |
| CN1282470C (en) | Traditional Chinese medicine for anti depression | |
| CN1511535A (en) | Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease | |
| CN101062374A (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof | |
| CN1546533A (en) | Hericium erinaceus sulfate proteoglycan, preparation method thereof and pharmaceutical compositions with the same as active component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XINFU PHARMACEUTICAL IND CO., LTD., HANGZHOU Effective date: 20070907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20070907 Address after: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee after: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311305 Ling'an Economic Development Zone, Zhejiang, Hangzhou Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee after: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. Address before: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee before: ZHEJIANG HANGZHOU XINFU PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20160623 Address after: Hangzhou City, Zhejiang province 311300 Ling'an City Kam South Street No. 9 Gua fan Patentee after: HANGZHOU XINFU SCIENCE & TECHNOLOGY Co.,Ltd. Address before: 311300 Jin Town, Zhejiang City, Ling'an Province Patentee before: YIFAN XINFU PHARMACEUTICAL Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070711 Termination date: 20210206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |